Clozapine treatment and risk of severe COVID-19 infection.

ABSTRACT:

Objective

To investigate whether patients with clozapine treatment are at an increased risk of a more severe COVID-19 infection as compared with patients on other antipsychotic drugs.

Methods

In this register-based cohort study, all residents (age 18 or older) in the Stockholm Region with a psychotic disorder diagnosis and antipsychotic treatment were included (N = 8 233) and followed from 1 March 2020 to 14 January 2021. The exposure was defined as clozapine treatment and the outcome measures (indicating a more severe COVID-19 infection) were: inpatient care, care within intensive care unit or death due to COVID-19 infection. Differences in outcome rates between exposed (n = 966) and unexposed (other antipsychotics; n = 7 267) were examined using Cox proportional hazards mo

SUBMITTER: Ohlis A 

PROVIDER: S-EPMC8653206 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature